Who are Edarbi's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cozaar, Cozzar tablet, Losartan (+) amlodipine, Candesartan cilexetil/Amlodipine besylate, Angiotensin receptor blocker, Micardis plus 80/12.5.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azilsartan-medoxomil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Edarbi — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Edarbi (AZILSARTAN MEDOXOMIL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Angiotensin 2 Receptor Blocker. Area: Cardiovascular.

marketed Angiotensin 2 Receptor Blocker AT1 receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Edarbi (AZILSARTAN MEDOXOMIL) — Arbor Pharms Ireland. Azilsartan blocks angiotensin II's vasoconstrictor and aldosterone-secreting effects by selectively binding to the AT1 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Edarbi TARGET	AZILSARTAN MEDOXOMIL	Arbor Pharms Ireland	marketed	Angiotensin 2 Receptor Blocker	AT1 receptor	2011-01-01
Cozaar	losartan	Merck & Co.	marketed	ARB (Angiotensin II receptor blocker)	AT1 receptor	1995-04-14
Cozzar tablet	Cozzar tablet	Chong Kun Dang Pharmaceutical	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (angiotensin II type 1 receptor)
Losartan (+) amlodipine	Losartan (+) amlodipine	Organon and Co	marketed	Angiotensin II receptor blocker + calcium channel blocker combination	AT1 receptor (losartan); L-type voltage-gated calcium channel (amlodipine)
Candesartan cilexetil/Amlodipine besylate	Candesartan cilexetil/Amlodipine besylate	HK inno.N Corporation	marketed	Angiotensin II receptor blocker / Calcium channel blocker combination	AT1 receptor (angiotensin II type 1 receptor) / L-type voltage-gated calcium channel
Angiotensin receptor blocker	Angiotensin receptor blocker	National University of Ireland, Galway, Ireland	marketed	Angiotensin receptor blocker	AT1 receptor (Angiotensin II type 1 receptor)
Micardis plus 80/12.5	Micardis plus 80/12.5	Heart Care Foundation	marketed	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); thiazide-sensitive sodium-chloride cotransporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-03-26 — Edarbi · 9066936 · US
2030-02-04 — Edarbi · 9169238 · US
2031-07-01 — Edarbi · 9387249 · US

Sponsor landscape (Angiotensin 2 Receptor Blocker class)

ANI Pharmaceuticals · 1 drug in this class
AbbVie · 1 drug in this class
Arbor Pharms Ireland · 1 drug in this class
Merck & Co. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Edarbi — Competitive Intelligence Brief. https://druglandscape.com/ci/azilsartan-medoxomil. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab